This pharma stock printed 3 all-time highs in January

Amid a turbulent year for the US pharmaceutical sector, the iShares U.S. Pharmaceuticals ETF (IHE), tracking major domestic pharma companies, has struggled, recording a meager 1% gain in 2023. However, amid this lackluster performance, Eli Lilly (NASDAQ: LLY) emerged as a standout performer, closing the year with remarkable gains exceeding 60%. Notably, January 2024 underscored the stock’s relentless surge, reaching three all-time highs within a week, with the latest peak at $639.76 on January 11, subsequen ...